These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

498 related items for PubMed ID: 17462889

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Comparison of the anticoagulant and antithrombotic effects of synthetic thrombin and factor Xa inhibitors.
    Hauptmann J, Kaiser B, Nowak G, Stürzebecher J, Markwardt F.
    Thromb Haemost; 1990 Apr 12; 63(2):220-3. PubMed ID: 2363124
    [Abstract] [Full Text] [Related]

  • 4. Development of an oxazolopyridine series of dual thrombin/factor Xa inhibitors via structure-guided lead optimization.
    Deng JZ, McMasters DR, Rabbat PM, Williams PD, Coburn CA, Yan Y, Kuo LC, Lewis SD, Lucas BJ, Krueger JA, Strulovici B, Vacca JP, Lyle TA, Burgey CS.
    Bioorg Med Chem Lett; 2005 Oct 15; 15(20):4411-6. PubMed ID: 16137886
    [Abstract] [Full Text] [Related]

  • 5. Selective inhibition of coagulation factors: advances in antithrombotic therapy.
    Bauer KA.
    Semin Thromb Hemost; 2002 Jun 15; 28 Suppl 2():15-24. PubMed ID: 12073176
    [Abstract] [Full Text] [Related]

  • 6. Selection of S18326 as a new potent and selective boronic acid direct thrombin inhibitor.
    Rupin A, Mennecier P, Lila C, de Nanteuil G, Verbeuren TJ.
    Thromb Haemost; 1997 Oct 15; 78(4):1221-7. PubMed ID: 9364988
    [Abstract] [Full Text] [Related]

  • 7. Effects of tannins from Geum japonicum on the catalytic activity of thrombin and factor Xa of blood coagulation cascade.
    Dong H, Chen SX, Kini RM, Xu HX.
    J Nat Prod; 1998 Nov 15; 61(11):1356-60. PubMed ID: 9834152
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Highly potent and selective substrate analogue factor Xa inhibitors containing D-homophenylalanine analogues as P3 residue: part 2.
    Stürzebecher A, Dönnecke D, Schweinitz A, Schuster O, Steinmetzer P, Stürzebecher U, Kotthaus J, Clement B, Stürzebecher J, Steinmetzer T.
    ChemMedChem; 2007 Jul 15; 2(7):1043-53. PubMed ID: 17541992
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM.
    Thromb Res; 2011 Jun 15; 127(6):497-504. PubMed ID: 20888031
    [Abstract] [Full Text] [Related]

  • 12. Generation of potent coagulation protease inhibitors utilizing zinc-mediated chelation.
    Young WB, Sprengeler P, Shrader WD, Li Y, Rai R, Verner E, Jenkins T, Fatheree P, Kolesnikov A, Janc JW, Cregar L, Elrod K, Katz B.
    Bioorg Med Chem Lett; 2006 Feb 15; 16(3):710-3. PubMed ID: 16257204
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Preparation of 1-(3-aminobenzo[d]isoxazol-5-yl)-1H-pyrazolo[4,3-d]pyrimidin-7(6H)-ones as potent, selective, and efficacious inhibitors of coagulation factor Xa.
    Li YL, Fevig JM, Cacciola J, Buriak J, Rossi KA, Jona J, Knabb RM, Luettgen JM, Wong PC, Bai SA, Wexler RR, Lam PY.
    Bioorg Med Chem Lett; 2006 Oct 01; 16(19):5176-82. PubMed ID: 16870435
    [Abstract] [Full Text] [Related]

  • 15. Are factor Xa inhibitors superior to thrombin inhibitors in anticoagulation?
    Stürzebecher J, Stürzebecher U.
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1988 Oct 01; 115(1-2):152-6. PubMed ID: 2459011
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Interaction of antistasin-related peptides with factor Xa: identification of a core inhibitory sequence.
    Ohta N, Brush M, Jacobs JW.
    Thromb Haemost; 1994 Dec 01; 72(6):825-30. PubMed ID: 7740449
    [Abstract] [Full Text] [Related]

  • 19. Design and structure-activity relationships of potent and selective inhibitors of blood coagulation factor Xa.
    Ewing WR, Becker MR, Manetta VE, Davis RS, Pauls HW, Mason H, Choi-Sledeski YM, Green D, Cha D, Spada AP, Cheney DL, Mason JS, Maignan S, Guilloteau JP, Brown K, Colussi D, Bentley R, Bostwick J, Kasiewski CJ, Morgan SR, Leadley RJ, Dunwiddie CT, Perrone MH, Chu V.
    J Med Chem; 1999 Sep 09; 42(18):3557-71. PubMed ID: 10479288
    [Abstract] [Full Text] [Related]

  • 20. Synthesis and structure-activity relationships of potent thrombin inhibitors: piperazides of 3-amidinophenylalanine.
    Stürzebecher J, Prasa D, Hauptmann J, Vieweg H, Wikström P.
    J Med Chem; 1997 Sep 12; 40(19):3091-9. PubMed ID: 9301673
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.